再生元制药(REGN.US)、赛诺菲(SNY.US)重磅抗炎药再获FDA积极监管决定

智通财经01-17

智通财经APP获悉，1月17日，再生元制药(REGN.US)和赛诺菲(SNY.US)宣布，美国FDA更新其重磅白细胞介素-4(IL-4)和白细胞介素-13(IL-13)抑制剂Dupixent(dupilumab)治疗特应性皮炎(AD)的标签，增加了针对12岁及以上、手和/或脚症状未受控制的中度至重度特应性皮炎患者的疗效和安全性数据。根据新闻稿，这些3期数据来自专门针对这一难治性患者群体所评估的首个...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2404666353?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-01-17 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2404666353","market":"hk","top_or_hot":-1,"title":"再生元制药(REGN.US)、赛诺菲(SNY.US)重磅抗炎药再获FDA积极监管决定","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，1月17日，再生元制药(REGN.US)和赛诺菲(SNY.US)宣布，美国FDA更新其重磅白细胞介素-4(IL-4)和白细胞介素-13(IL-13)抑制剂Dupixent(dupilumab)治疗特应性皮炎(AD)的标签，增加了针对12岁及以上、手和/或脚症状未受控制的中度至重度特应性皮炎患者的疗效和安全性数据。根据新闻稿，这些3期数据来自专门针对这一难治性患者群体所评估的首个...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1056980.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>再生元制药(REGN.US)、赛诺菲(SNY.US)重磅抗炎药再获FDA积极监管决定</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n再生元制药(REGN.US)、赛诺菲(SNY.US)重磅抗炎药再获FDA积极监管决定\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-17 21:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1056980.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，1月17日，再生元制药(REGN.US)和赛诺菲(SNY.US)宣布，美国FDA更新其重磅白细胞介素-4(IL-4)和白细胞介素-13(IL-13)抑制剂Dupixent(dupilumab)治疗特应性皮炎(AD)的标签，增加了针对12岁及以上、手和/或脚症状未受控制的中度至重度特应性皮炎患者的疗效和安全性数据。根据新闻稿，这些3期数据来自专门针对这一难治性患者群体所评估的首个...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1056980.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1056980.html","article_id":"2404666353","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2404666353","pubTimestamp":1705498286,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，1月17日，再生元制药和赛诺菲宣布，美国FDA更新其重磅白细胞介素-4和白细胞介素-13抑制剂Dupixent治疗特应性皮炎的标签，增加了针对12岁及以上、手和/或脚症状未受控制的中度至重度特应性皮炎患者的疗效和安全性数据。此前，Dupixent单抗已被FDA批准治疗包括特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉病、结节性痒疹和嗜酸性食管炎等疾病。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK1574":"生物医药B类股","BK4007":"制药","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","SNY":"赛诺菲安万特","01477":"欧康维视生物-B","REGN":"再生元制药公司","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1917777945.USD":"安联专题基金Cl AT Acc","BK1191":"制药","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Heavy anti-inflammatory drugs of Regeneron Pharmaceuticals (REGN.US) and Sanofi (SNY.US) were actively supervised by FDA again","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1,"REGN":1,"01477":1},"content_text":"智通财经APP获悉，1月17日，再生元制药(REGN.US)和赛诺菲(SNY.US)宣布，美国FDA更新其重磅白细胞介素-4(IL-4)和白细胞介素-13(IL-13)抑制剂Dupixent(dupilumab)治疗特应性皮炎(AD)的标签，增加了针对12岁及以上、手和/或脚症状未受控制的中度至重度特应性皮炎患者的疗效和安全性数据。根据新闻稿，这些3期数据来自专门针对这一难治性患者群体所评估的首个生物制品试验。此外，Dupixent在欧盟的标签亦已更新，其他国家/地区的监管申请正在进行中。这次标签更新主要是基于LIBERTY-AD-HAFT临床3期试验的数据。在试验中，患者每两周接受Dupixent(n=67)或安慰剂(n=66)治疗。分析显示，Dupixent组患者的皮肤症状获得清除或几乎清除的患者数目是安慰剂组的两倍多，瘙痒得到改善的患者数量则是安慰剂组的近四倍。具体而言，在主要终点的评估上，第16周时，有40%接受Dupixent治疗患者手脚的皮肤症状获得清除或几乎清除，而此数值在安慰剂组仅为17%。据悉，Dupixent是一种完全人源化的单克隆抗体，可抑制IL-4和IL-13通路的信号传导。此前，Dupixent单抗已被FDA批准治疗包括特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉病(CRSwNP)、结节性痒疹和嗜酸性食管炎(EoE)等疾病。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2404666353"}